Knuff & Co LLC Has $2.66 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Knuff & Co LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,101 shares of the biopharmaceutical company’s stock after selling 3,070 shares during the quarter. Knuff & Co LLC’s holdings in Gilead Sciences were worth $2,656,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of GILD. Eads & Heald Wealth Management acquired a new position in Gilead Sciences in the 1st quarter worth about $201,000. Monarch Capital Management Inc. increased its holdings in Gilead Sciences by 2.9% in the fourth quarter. Monarch Capital Management Inc. now owns 67,369 shares of the biopharmaceutical company’s stock valued at $3,925,000 after purchasing an additional 1,888 shares during the period. Kestra Private Wealth Services LLC raised its position in Gilead Sciences by 71.2% during the 4th quarter. Kestra Private Wealth Services LLC now owns 38,271 shares of the biopharmaceutical company’s stock worth $2,168,000 after purchasing an additional 15,917 shares during the last quarter. Virginia Retirement Systems ET AL bought a new stake in Gilead Sciences in the first quarter valued at approximately $7,071,000. Finally, LS Investment Advisors LLC lifted its holdings in Gilead Sciences by 3.1% in the fourth quarter. LS Investment Advisors LLC now owns 61,892 shares of the biopharmaceutical company’s stock valued at $3,606,000 after buying an additional 1,881 shares during the period. 76.36% of the stock is owned by institutional investors and hedge funds.

GILD stock opened at $68.53 on Friday. The company has a market capitalization of $85.95 billion, a price-to-earnings ratio of 70.65, a PEG ratio of 0.67 and a beta of 0.51. Gilead Sciences, Inc. has a fifty-two week low of $56.56 and a fifty-two week high of $79.31. The company has a debt-to-equity ratio of 1.65, a quick ratio of 3.15 and a current ratio of 3.25. The stock has a fifty day moving average of $65.74 and a 200-day moving average of $63.06.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, topping the Zacks’ consensus estimate of $2.06 by $0.02. Gilead Sciences had a return on equity of 37.77% and a net margin of 5.48%. The firm had revenue of $6.42 billion during the quarter, compared to analyst estimates of $6.78 billion. Equities analysts predict that Gilead Sciences, Inc. will post 7.06 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th will be given a $0.71 dividend. The ex-dividend date of this dividend is Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.14%. Gilead Sciences’s dividend payout ratio (DPR) is currently 46.25%.

In other news, EVP Brett A. Pletcher sold 1,486 shares of the stock in a transaction on Thursday, March 11th. The shares were sold at an average price of $63.36, for a total value of $94,152.96. Following the transaction, the executive vice president now owns 29,166 shares of the company’s stock, valued at approximately $1,847,957.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard James Whitley sold 20,282 shares of Gilead Sciences stock in a transaction on Monday, May 3rd. The stock was sold at an average price of $64.57, for a total transaction of $1,309,608.74. Following the sale, the director now directly owns 51,404 shares of the company’s stock, valued at $3,319,156.28. The disclosure for this sale can be found here. 0.13% of the stock is currently owned by insiders.

GILD has been the subject of several recent analyst reports. Sanford C. Bernstein raised Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $80.00 target price for the company in a research note on Thursday, April 1st. Redburn Partners upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a research report on Tuesday, March 30th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 30th. Credit Suisse Group boosted their target price on Gilead Sciences from $65.00 to $66.00 and gave the company a “neutral” rating in a research report on Friday, February 5th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Friday, May 7th. Ten analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $99.22.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: What is systematic risk?

Want to see what other hedge funds are holding GILD? Visit to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.